1 Introduction In recent years, with economic development and changes in diet, the incidence of lipid metabolic diseases, such as non-alcoholic fatty liver disease (NAFLD), atherosclerosis (AS), obesity, and hyperlipidemia, has increased, placing a significant burden on human health and the health insurance system (Loomba et al., 2021; Fan and Watanabe, 2022). Elevated lipid levels are a common feature of these diseases, and thus lipid-lowering therapies are essential for their treatment.